31 results about "Cycloartenyl ferulate" patented technology

The invention discloses a composition taking cycloartenyl ferulate and 24-methylene cycloartenyl ferulate as active ingredients, a preparation of the composition used as a medicine, and an application of the preparation. The total content of the cycloartenyl ferulate and the 24-methylene cycloartenyl ferulate is over 90 percent of the total active ingredients by weight percentage. As the medicine, the composition can be injection and frozen-dried powder injection and also can be an oral solid preparation, a medicine composition used for treating autonomic imbalance, climacteric syndrome, primary dysmenorrheal and premenstrual tension, periodic psychosis, vascular headache, head trauma syndrome, gastrointestinal imbalance and hyperlipemia, etc.

The invention discloses a technical scheme for preparing cycloartenyl ferulate from raw material of oryzanol and further discloses the application of the prepared cycloartenyl ferulate and surfactant to medicinal compound and preparation. Due to the purification process of the cycloartenyl ferulate by recrystallization, the purity of the cycloartenyl ferulate can achieve over 80%. The invention also discloses injection of the compound, particularly freeze-dried powder injection.

The invention discloses the purpose of gamma-oryzanol as functional food additives. The purity of the gamma-oryzanol is above 80% calculated by weight percentage. The additive can be added into functional food for lowering blood lipid, preventing disorder of body rhythm, and alleviating and improving weariness and fatigue due to disorder of body rhythm.

The invention discloses a pharmaceutical composition of cycloartenyl ferulate oryzanolum, which comprises cycloartenyl ferulate oryzanolum, phospholipid, bile acid and / or salt of bile acid. The pharmaceutical composition effectively improves the water solubility and the stability of the cycloartenyl ferulate oryzanolum and has better grain diameter and stability than the prior product, and further, the invention provides three product forms including injectio, freeze-dried powder and kits of the pharmaceutical composition, and preparation methods thereof.

The invention discloses cycloartenyl ferulate solid dispersion, which comprises cycloartenyl ferulate and povidone serving as a carrier material. The invention further discloses a medicinal preparation and a preparation method of the solid dispersion. Experiments prove that the solid dispersion makes obvious technical progress in technical indexes such as dissolution rate, stability, water solubility, bioavailability and the like.

The invention relates to a method of preparing high-purity monomer cycloartenyl ferulate, 24-methylene cycloartenyl ferulate, campesterol ferulate and sitosterol ferulate from a rice bran extract through separation by counter-current chromatography. The four active substances such as high-purity cycloartenyl ferulate are prepared from the rice bran extract through separation by the counter-currentchromatography; a solvent systems comprises three ingredients: petroleum ether or normal paraffin, dichloromethane and acetonitrile or fatty alcohol at a volume ratio of 10:(0-3):(7-12); the method is applicable to preparation of monomer cycloartenyl ferulate, 24-methylene cycloartenyl ferulate, campesterol ferulate and sitosterol ferulate by using various models of counter-current chromatographs; many crude products or synthetic mixtures can be introduced directly; the purity of separated cycloartenyl ferulate and sitosterol ferulate reaches above 95%; and the purity of 24-methylene cycloartenyl ferulate and campesterol ferulate reaches above 90%.

The invention discloses a pharmaceutical composition of cycloartenyl ferulate oryzanolum and a 24-methylene cycloartenyl oryzanolum compound, which comprises the cycloartenyl ferulate oryzanolum, the 24-methylene cycloartenyl oryzanolum compound, phospholipid, bile acid and / or salt of bile acid. The pharmaceutical composition effectively improves the water solubility and the stability of the cycloartenyl ferulate oryzanolum and the 24-methylene cycloartenyl oryzanolum compound and has better grain diameter and stability than the prior product, and further, the invention provides three productforms including injectio, freeze-dried powder and kits of the pharmaceutical composition, and preparation methods thereof.

The invention discloses a high-efficiency HPLC analysis method of oryzanol, belonging to the analytical chemistry field. The contents of cycloartenyl ferulate and 24-methylene-cycloartenyl ferulate in the oryzanol, oryzanol extraction separation and purification product, oryzanol medicine can be quickly and accurately analyzed using the HPLC analysis method and at the same time the contents of the other impurities can be analyzed. The high-efficiency HPLC analysis method can also be used for the oryzanol medicine quality research such as oryzanol medicine stability, breakage or the like.

The invention discloses a medicine composition of cycloartenyl ferulate. The medicine composition solves the problem that the cycloartenyl ferulate cannot dissolve in water easily and contains cycloartenyl ferulate and polyoxyl stearate. Stable and water-soluble oryzanol medicine composition solution is obtained by adding the cycloartenyl ferulate into the molten polyoxyl stearate. The invention further discloses a preparation method and preparation application of the medicine composition of cycloartenyl ferulate.

The invention provides a method for preparing five ferulate single components by taking soapstock containing oryzanol as a raw material. The method comprises the following steps: 1) carrying out alkali-alcohol hot dissolution and filtering while the soapstock is hot; 2) carrying out acid precipitation and filtration; 3) degreasing and decoloring by using a lipophilic organic solvent; and (4) preparing thin-layer chromatography for separation; wherein the condition is that the content of the oryzanol in a precipitate crude product obtained after decoloring in the step (3) is 70-80wt%. The method is characterized in that soapstock with the oryzanol content of 10-20% is used as a raw material, a product with the oryzanol content of 70-80 wt% is obtained through a specific pretreatment purifying step, and then a monomer substance is separated and prepared through thin-layer chromatography; the purity of the five prepared monomers, namely 24-methylene cycloartanyl ferulate, cycloartenyl ferulate, cycloartanyl ferulate, campesterol ferulate and beta-sitosterol ferulate is greater than 90%; and the ferulate single components can be used as a reference substance for content determination,and can be used for external standard method content calculation and qualitative peak position calibration.

The invention relates to the application of sterol phenolic ester to preparation of health care foods or medicines for resisting breast cancer, in particular to the application of sterol phenolic ester to preparation of breast cancer prevention and treatment medicine. The sterol phenolic ester is at least one of 24-methylenecycloartenyl ferulate, cycloartenyl ferulate, beta-sitosteryl ferulate, stigmasteryl ferulate, campesteryl ferulate, campesteryl alkanol ferulate, campesteryl ferulate, 24-methylcholestanyl ferulate, 24- methenylcholestanyl ferulate and dihydro-sitosteryl ferulate.

The invention discloses a pharmaceutical composition of 24-methylene cycloartenyl oryzanolum, which comprises the 24-methylene cycloartenyl oryzanolum, phospholipid, bile acid and / or salt of bile acid. The pharmaceutical composition effectively improves the water solubility and the stability of the 24-methylene cycloartenyl oryzanolum and has better grain diameter and stability than the prior product, and further, the invention provides three product forms including injectio, freeze-dried powder and kits of the pharmaceutical composition, and preparation methods thereof.

The invention discloses oryzanol, oryzanol extracts, cycloartenyl ferulate and 24-methylene cycloartenyl ferulate, relating to application of cycloartenyl ferulate in preparing medicaments for treating maintaining disorder type insomnia, particularly chronic maintaining disorder type insomnia. The experiments performed by the applicant show that the oryzanol, the oryzanol extracts, the cycloartenyl ferulate and the 24-methylene cycloartenyl ferulate all have certain treatment effects on treating the maintaining disorder type insomnia, wherein the cycloartenyl ferulate has an excellent effect on treating the maintaining disorder type insomnia, particularly the chronic maintaining disorder type insomnia.

The invention discloses a composition taking cycloartenyl ferulate and 24-methylene cycloartenyl ferulate as active ingredients, a preparation of the composition used as a medicine, and an application of the preparation. The total content of the cycloartenyl ferulate and the 24-methylene cycloartenyl ferulate is over 90 percent of the total active ingredients by weight percentage. As the medicine, the composition can be injection and frozen-dried powder injection and also can be an oral solid preparation, a medicine composition used for treating autonomic imbalance, climacteric syndrome, primary dysmenorrheal and premenstrual tension, periodic psychosis, vascular headache, head trauma syndrome, gastrointestinal imbalance and hyperlipemia, etc.

The invention discloses a medicinal composition of 24-methylene cycloartenyl ferulate, which solves the problem that the 24-methylene cycloartenyl ferulate is slightly soluble in water. The medicinal composition comprises the 24-methylene cycloartenyl ferulate and polyoxyl stearate; and a stable and water-soluble oryzanol medicinal composition solution is obtained by adding the 24-methylene cycloartenyl ferulate into the fused polyoxyl stearate. The invention also discloses a preparation method of the medicinal composition solution and preparation application.

The invention discloses the application of a component containing cycloartenyl ferulate and 24-methylene cycloartenyl ferulate as active components as functional food additive. The total content of cycloartenyl ferulate and 24-methylene cycloartenyl ferulate in the additive accounts for more than 90wt% the total content of the active components. The component can be added into functional food as an additive and has the effects of reducing blood fat, preventing body rhythm disorder, and relieving and alleviating fatigue and lassitude caused by rhythm disorder.

The invention discloses a technical scheme for preparing cycloartenyl ferulate from raw material of oryzanol and further discloses the application of the prepared cycloartenyl ferulate and surfactant to medicinal compound and preparation. Due to the purification process of the cycloartenyl ferulate by recrystallization, the purity of the cycloartenyl ferulate can achieve over 80%. The invention also discloses injection of the compound, particularly freeze-dried powder injection.

The invention discloses a pharmaceutical composition comprising cycloartenyl ferulate, which solves the problem that cycloartenyl ferulate is insoluble in water. The pharmaceutical composition disclosed by the invention comprises cycloartenyl ferulate and polyoxyl[40]stearate. A stable and water-soluble oryzanol pharmaceutical composition solution is obtained by adding cycloartenyl ferulate into molten polyoxyl[40]stearate. Further, the invention discloses a preparation method of the pharmaceutical composition solution and applications of the preparation.

The invention provides a method for preparing five ferulate single components by taking soapstock containing oryzanol as a raw material. The method comprises the following steps: 1) carrying out alkali-alcohol hot dissolution and filtering while the soapstock is hot; 2) carrying out acid precipitation and filtration; 3) degreasing and decoloring by using a lipophilic organic solvent; and (4) preparing thin-layer chromatography for separation; wherein the condition is that the content of the oryzanol in a precipitate crude product obtained after decoloring in the step (3) is 70-80wt%. The method is characterized in that soapstock with the oryzanol content of 10-20% is used as a raw material, a product with the oryzanol content of 70-80 wt% is obtained through a specific pretreatment purifying step, and then a monomer substance is separated and prepared through thin-layer chromatography; the purity of the five prepared monomers, namely 24-methylene cycloartanyl ferulate, cycloartenyl ferulate, cycloartanyl ferulate, campesterol ferulate and beta-sitosterol ferulate is greater than 90%; and the ferulate single components can be used as a reference substance for content determination,and can be used for external standard method content calculation and qualitative peak position calibration.

The invention discloses a pharmaceutical composition comprising cycloartenyl ferulate, which solves the problem that cycloartenyl ferulate is insoluble in water. The pharmaceutical composition disclosed by the invention comprises cycloartenyl ferulate and polyoxyl[40]stearate. A stable and water-soluble oryzanol pharmaceutical composition solution is obtained by adding cycloartenyl ferulate into molten polyoxyl[40]stearate. Further, the invention discloses a preparation method of the pharmaceutical composition solution and applications of the preparation.

The invention discloses a medicinal composition of 24-methylene cycloartenyl ferulate, which solves the problem that the 24-methylene cycloartenyl ferulate is slightly soluble in water. The medicinal composition comprises the 24-methylene cycloartenyl ferulate and polyoxyl stearate; and a stable and water-soluble oryzanol medicinal composition solution is obtained by adding the 24-methylene cycloartenyl ferulate into the fused polyoxyl stearate. The invention also discloses a preparation method of the medicinal composition solution and preparation application.

The invention relates to the application of sterol phenolic ester to preparation of health care foods or medicines for resisting breast cancer, in particular to the application of sterol phenolic ester to preparation of breast cancer prevention and treatment medicine. The sterol phenolic ester is at least one of 24-methylenecycloartenyl ferulate, cycloartenyl ferulate, beta-sitosteryl ferulate, stigmasteryl ferulate, campesteryl ferulate, campesteryl alkanol ferulate, campesteryl ferulate, 24-methylcholestanyl ferulate, 24- methenylcholestanyl ferulate and dihydro-sitosteryl ferulate.

The invention discloses a pharmaceutical composition of cycloartenyl ferulate oryzanolum, which comprises cycloartenyl ferulate oryzanolum, phospholipid, bile acid and / or salt of bile acid. The pharmaceutical composition effectively improves the water solubility and the stability of the cycloartenyl ferulate oryzanolum and has better grain diameter and stability than the prior product, and further, the invention provides three product forms including injectio, freeze-dried powder and kits of the pharmaceutical composition, and preparation methods thereof.

The invention discloses a 24-methylenecycloartanol ferulic acid ester which is used as the additive for functional foods. The purity of the 24-methylenecycloartanol ferulic acid ester is above 80% in weight percentage. As the additive, the 24-methylenecycloartanol ferulic acid ester is added into functional foods and has good effects of decreasing blood lipid, preventing the imbalance of body rhythm, relieving and eliminating the burnout and fatigue caused by the imbalance of body rhythm.

The invention discloses a high-efficiency HPLC analysis method of oryzanol, belonging to the analytical chemistry field. The contents of cycloartenyl ferulate and 24-methylene-cycloartenyl ferulate in the oryzanol, oryzanol extraction separation and purification product, oryzanol medicine can be quickly and accurately analyzed using the HPLC analysis method and at the same time the contents of the other impurities can be analyzed. The high-efficiency HPLC analysis method can also be used for the oryzanol medicine quality research such as oryzanol medicine stability, breakage or the like.

The invention discloses oryzanol, oryzanol extracts, cycloartenyl ferulate and 24-methylene cycloartenyl ferulate, relating to application of cycloartenyl ferulate in preparing medicaments for treating maintaining disorder type insomnia, particularly chronic maintaining disorder type insomnia. The experiments performed by the applicant show that the oryzanol, the oryzanol extracts, the cycloartenyl ferulate and the 24-methylene cycloartenyl ferulate all have certain treatment effects on treating the maintaining disorder type insomnia, wherein the cycloartenyl ferulate has an excellent effect on treating the maintaining disorder type insomnia, particularly the chronic maintaining disorder type insomnia.

The present invention discloses a pharmaceutical composition containing a complex of cycloartenyl ferulate and 24-methylene cycloartanyl ferulate, phospholipids, cholic acids and / or salts thereof. The water-solubility and the stability of the complex of cycloartenyl ferulate and 24-methylene cycloartanyl ferulate have been effectively improved by being made into the pharmaceutical composition of the present invention. And the particle diameter and the stability of the said pharmaceutical composition are superior to that of the existing products. Furthermore, the present invention provides an injectable fluid, an injectable lyophilized powder and a kit containing the pharmaceutical composition as well as the preparation methods thereof.

Provided are methods or processes for producing ferulic acid from a plant material, for example, a rice bran or its derivatives. Provided are methods comprising an ion swapping and solvent extraction process followed by a chromatographic separation operations that are coupled into a process which functions to recover a fraction rich in gamma-oryzanol, thus enabling the subsequent production of a high purity ferulic acid. Provided are methods comprising an ion swapping and solvent extraction process followed by a process which functions to recover a fraction rich in gamma-oryzanol, or a mixture of ferulic acid esters of phytosterols and triterpenoids, optionally comprising cycloartenyl ferulate, 24-methylenecycloartanyl ferulate, and / or campesteryl ferulate, to enable the production of a high purity ferulic acid. Provided are methods comprising a saponification and solvent extraction process followed by recovering a fraction rich in gamma-oryzanol to enable the production of a high purity ferulic acid.